Data from an analysis of the landmark CLEAR Outcomes trial suggests bempedoic acid could prove useful ... read more

At the European Society of Cardiology (ESC) Congress 2023, the spotlight was on mavacamten and its ... read more

Data from VALOR-HCM LTE suggest use of the cardiac myosin inhibitor mavacamten (Camzyos) could reduce the ... read more

For frail elderly patients with atrial fibrillation, switching from a vitamin K antagonist (VKA) treatment to ... read more

For endocrinologists and the diabetes care team, GLP-1 receptor agonists have been a familiar face for ... read more

The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects ... read more

The understanding and management of heart failure with preserved ejection fraction (HFpEF) has undergone a transformation ... read more

A pair of studies and focused guideline update from the European Society of Cardiology (ESC) Congress ... read more